« NeurotrophinCell Success | Main | Argument Against Nationalized Research »
October 11, 2004
More On NeurotrophinCell
"This is the first time that technology of this kind has been proven in a controlled pre-clinical setting to prevent the degeneration of the brain due to Huntington's disease-like conditions,"...
The technology protects the cells from attack by the body's immune system.
This allowing them to produce several factors important to the health and survival of the brain.
Alfred Vasconcellos, chief executive of Living Cell Technologies's US operation, LCT BioPharma, said the work had shown "the ability of LCT's technology to protect brain tissue that would otherwise die, potentially forestalling and preventing the debilitating consequences of this disease".
LCT chief operating officer Roger Coats said the company had another 12 months or so of pre-clinical trials to complete before moving into clinical trials.
Posted by Dave at October 11, 2004 10:20 AM
Trackback Pings
TrackBack URL for this entry:
http://www.huntingtons.info/MT/mt-tb.cgi/610
Comments
Post a comment
Thanks for signing in, . Now you can comment. (sign out)
(If you haven't left a comment here before, you may need to be approved by the site owner before your comment will appear. Until then, it won't appear on the entry. Thanks for waiting.)